Discovery of a Potent, Selective, and Orally Bioavailable Tool Compound for Probing the Role of Lysophosphatidic Acid Type 2 Receptor Antagonists in Fibrotic Disorders.

导出原文传递

翻译打印收藏纠错

作者： Elisabetta,Armani ^[1] ; Andrea,Rizzi ^[1] ; Nicolò,Iotti ^[1] ; Francesca,Saccani ^[1] ; Maria Rosaria,Di Lascia ^[1] ; Laura,Tigli ^[1] ; Alice,Pappani ^[1] ; Gessica,Marchini ^[1] ; Annalisa,Murgo ^[1] ; Anna Maria,Capelli ^[1] ; Maurizio,Delcanale ^[1] ; Paola,Puccini ^[1] ; Gino,Villetti ^[1] ; Maurizio,Civelli ^[1] ; Claudia,Beato ^[2] ; Marta,Giuliani ^[2] ; Claudia,Mundi ^[2] ; Francesca,Murarolli ^[2] ; Mafalda,Pagano ^[2] ; Luca F,Raveglia ^[2] ; Rosaria,Remelli ^[2] ; Gabriele,Amari ^[1]

作者单位： Chiesi Farmaceutici S.p.A, Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy. ^[1] Aptuit, an Evotec Company, v ia Alessandro Fleming, 4, 37135 Verona, Italy. ^[2]

主题词人类(Humans);受体, 溶血磷脂酸(Receptors, Lysophosphatidic Acid);特发性肺纤维化(Idiopathic Pulmonary Fibrosis);溶血磷脂素类(Lysophospholipids)

DOI 10.1021/acs.jmedchem.2c02087

PMID 37017110

发布时间 2023-06-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交